News & Updates

Treatment with nelonemdaz, a multitarget neuroprotectant that selectively blocks N-methyl-D-aspartate receptors and scavenges free radicals, does not appear to significantly improve stroke outcomes as compared with placebo, although nelonemdaz-treated patients show a greater tendency toward achieving modified Rankin Scale scores of 0–2 at 12 weeks, according to the results of a phase II study.

Individuals with nonaffective psychotic disorders appear to have a twofold higher risk of developing subsequent dementia compared with those who do not have such disorders, as reported in a recent study.

There appears to only be a very weak to no significant correlation between hypertension and cognitive function in late life, reports a recent study.

Early initiation of nonvitamin K antagonist oral anticoagulants (NOACs) after acute ischaemic stroke in patients with atrial fibrillation (AF) appears to yield similar outcomes when compared with delayed initiation, as shown in the results of the TIMING* study.